Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma

Next Previous
Trial Profile

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IGF 1R antisense therapy (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Acronyms ImmuneSense
  • Sponsors Imvax

Most Recent Events

  • 06 Apr 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Sep 2025.
  • 29 Jan 2025 According to an Imvax media release, the company has secured $29 million financing round from existing investors, and collectively the Company has raised $86 million to support the completion of this study, over the past 21 months. This financing provides operating flexibility well beyond the readout of the top-line results for this trial.
  • 11 Nov 2024 According to an Imvax media release, company announced data from this study will be present at the 2024 Society for NeuroOncology (SNO) 29th Annual Meeting in Houston, Texas, from November 21-24, 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top